#USA #Precision Medicine #Carlsbad #Tyra Biosciences #FGFR Biology

Tyra Biosciences to Connect with Investors at Upcoming Conferences

Tyra Biosciences, Inc. (Nasdaq: TYRA), a pioneering clinical-stage biotechnology firm, is gearing up to participate in pivotal investor events next month. With a dedication to developing cutting-edge precision medicines, Tyra is focused on addressing vast opportunities in the realm of Fibroblast Growth Factor Receptor (FGFR) biology, a crucial area in targeted cancer therapies.

Upcoming Events

Tyra Biosciences is set to attend two notable conferences:
1. Jefferies London Healthcare Conference
- Format: Hybrid presentation (slides, moderated Q&A), along with one-on-one meetings with investors
- Date/Time: November 19, 2025, at 4:00 PM GMT
- Location: London, UK
2. 37th Annual Piper Healthcare Conference
- Format: One-on-one investor meetings
- Date: December 2-4, 2025
- Location: New York, NY

Investors can access a live webcast of the Jefferies event via the 'For Investors' section on Tyra Biosciences' official website, which will also be available for replay afterwards.

Understanding Tyra Biosciences

Founded and based in Carlsbad, California, Tyra is committed to innovation in the biotechnology sector. The company's specialized focus is on developing next-generation precision medicines, empowering the fight against diseases tied to FGFR biology. Notably, Tyra has cultivated a unique in-house precision medicine platform known as SNÅP, which facilitates rapid and precise drug design through a series of iterative molecular snapshots. This innovative approach assists in predicting genetic alterations that might lead to acquired resistance against existing therapies.

Pioneering Medicines

The company's expertise in FGFR biology has enabled them to construct a distinctly positioned pipeline containing several clinical-stage programs that aim to treat targeted oncology cases and genetically defined conditions. Among the forefront of its innovations is dabogratinib, the leading precision medicine from Tyra, envisioned as a potential first-in-class selective FGFR3 inhibitor.

Currently, the planned clinical development of dabogratinib includes:

• - BEACH301: for pediatric achondroplasia (ACH)
• - SURF302: targeting intermediate-risk non-muscle invasive bladder cancer (IR-NMIBC)
• - SURF303: for low-grade upper tract urothelial carcinoma (LG-UTUC), and possibly metastatic urothelial carcinoma (mUC)

Moreover, Tyra is exploring TYRA-430, an oral, investigational FGFR4/3-biased inhibitor designated for FGF19+/FGFR4-driven cancers. This investigational product is currently undergoing examination in the SURF431 study targeting advanced hepatocellular carcinoma. Additionally, TYRA-200, an oral investigational FGFR1/2/3 inhibitor, is included in the SURF201 trial for metastatic intrahepatic cholangiocarcinoma.

Continuing Innovation

Tyra Biosciences is at the forefront of a critical landscape in biotechnology, with its ongoing commitment to innovation and patient outcomes. As they prepare to share insights and progress during these key investor conferences, the biotechnology community eagerly anticipates the potential advancements that Tyra may unveil, shaping the next era of targeted therapies.

For more details on Tyra Biosciences, including their science and pipeline, visit Tyra's official website and connect with them on LinkedIn.

Conclusion

These upcoming conferences mark a significant step for Tyra Biosciences in engaging with investors who are keen to learn about groundbreaking advancements in precision medicine and the company's strategic direction. As Tyra continues to innovate within the FGFR biology space, they are poised to make substantial contributions to the field, enhancing treatment options for patients in need.